Bicycle Therapeutics Plc ADR [BCYC] stock is trading at $26.46, up 5.67%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCYC shares have gain 12.12% over the last week, with a monthly amount drifted -2.86%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] stock has seen the most recent analyst activity on September 06, 2024, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $35. Previously, B. Riley Securities downgraded its rating to Neutral on August 07, 2024, and dropped its price target to $28. On September 11, 2023, upgrade upgraded it’s rating to Buy. Cowen started tracking the stock assigning a Outperform rating. Barclays initiated its recommendation with a Overweight and recommended $30 as its price target on July 28, 2022. In a note dated April 13, 2022, B. Riley Securities downgraded an Neutral rating on this stock and revised its target price from $62 to $33.
Bicycle Therapeutics Plc ADR [BCYC] stock has fluctuated between $12.54 and $28.20 over the past year. Currently, Wall Street analysts expect the stock to reach $65.33 within the next 12 months. Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] shares were valued at $26.46 at the most recent close of the market. An investor can expect a potential return of 146.9% based on the average BCYC price forecast.
Analyzing the BCYC fundamentals
Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] reported sales of 39.59M for the trailing twelve months, which represents a drop of -18.04%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -5.22%, Pretax Profit Margin comes in at -4.69%, and Net Profit Margin reading is -4.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.33 and Total Capital is -0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.02 points at the first support level, and at 23.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.63, and for the 2nd resistance point, it is at 28.80.
Ratios To Look Out For
For context, Bicycle Therapeutics Plc ADR’s Current Ratio is 14.77. As well, the Quick Ratio is 14.77, while the Cash Ratio is 13.81. Considering the valuation of this stock, the price to sales ratio is 46.08, the price to book ratio is 2.09.
Transactions by insiders
Recent insider trading involved Lee Kevin, CHIEF EXECUTIVE OFFICER, that happened on Oct 03 ’24 when 3212.0 shares were sold. CHIEF PROD & SUPPLY CHAIN OFF, Hannay Michael Charles Ferguso completed a deal on Oct 03 ’24 to sell 247.0 shares. Meanwhile, CHIEF TECHNOLOGY OFFICER Skynner Michael sold 972.0 shares on Oct 03 ’24.
